These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 17353198)

  • 1. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
    Ji Z; Mei FC; Xie J; Cheng X
    J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal response to Hedgehog signaling restrains pancreatic cancer progression.
    Lee JJ; Perera RM; Wang H; Wu DC; Liu XS; Han S; Fitamant J; Jones PD; Ghanta KS; Kawano S; Nagle JM; Deshpande V; Boucher Y; Kato T; Chen JK; Willmann JK; Bardeesy N; Beachy PA
    Proc Natl Acad Sci U S A; 2014 Jul; 111(30):E3091-100. PubMed ID: 25024225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer.
    Wei L; Xu Z
    Int J Cancer; 2011 Jul; 129(2):275-84. PubMed ID: 20839260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells.
    Veit C; Genze F; Menke A; Hoeffert S; Gress TM; Gierschik P; Giehl K
    Cancer Res; 2004 Aug; 64(15):5291-300. PubMed ID: 15289335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways.
    Stecca B; Mas C; Clement V; Zbinden M; Correa R; Piguet V; Beermann F; Ruiz i Altaba A
    Proc Natl Acad Sci U S A; 2007 Apr; 104(14):5895-900. PubMed ID: 17392427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway.
    Schnidar H; Eberl M; Klingler S; Mangelberger D; Kasper M; Hauser-Kronberger C; Regl G; Kroismayr R; Moriggl R; Sibilia M; Aberger F
    Cancer Res; 2009 Feb; 69(4):1284-92. PubMed ID: 19190345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
    Adamopoulos C; Cave DD; Papavassiliou AG
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
    Collisson EA; Trejo CL; Silva JM; Gu S; Korkola JE; Heiser LM; Charles RP; Rabinovich BA; Hann B; Dankort D; Spellman PT; Phillips WA; Gray JW; McMahon M
    Cancer Discov; 2012 Aug; 2(8):685-93. PubMed ID: 22628411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer.
    Seto M; Ohta M; Asaoka Y; Ikenoue T; Tada M; Miyabayashi K; Mohri D; Tanaka Y; Ijichi H; Tateishi K; Kanai F; Kawabe T; Omata M
    Mol Carcinog; 2009 Aug; 48(8):703-12. PubMed ID: 19142899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
    Wu CY; Carpenter ES; Takeuchi KK; Halbrook CJ; Peverley LV; Bien H; Hall JC; DelGiorno KE; Pal D; Song Y; Shi C; Lin RZ; Crawford HC
    Gastroenterology; 2014 Dec; 147(6):1405-16.e7. PubMed ID: 25311989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.
    Wang X; Breuer J; Garbe S; Giordano F; Brossart P; Feldmann G; Bisht S
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCL/TAL1 interrupting locus derepresses GLI1 from the negative control of suppressor-of-fused in pancreatic cancer cell.
    Kasai K; Inaguma S; Yoneyama A; Yoshikawa K; Ikeda H
    Cancer Res; 2008 Oct; 68(19):7723-9. PubMed ID: 18829525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.
    Eser S; Reiff N; Messer M; Seidler B; Gottschalk K; Dobler M; Hieber M; Arbeiter A; Klein S; Kong B; Michalski CW; Schlitter AM; Esposito I; Kind AJ; Rad L; Schnieke AE; Baccarini M; Alessi DR; Rad R; Schmid RM; Schneider G; Saur D
    Cancer Cell; 2013 Mar; 23(3):406-20. PubMed ID: 23453624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
    Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
    Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
    J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
    Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W
    Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.